Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis

Clicks: 406
ID: 269154
2018
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #5 of 38 articles by views in clinical gastroenterology and hepatology : the official clinical practice journal of the american gastroenterological association

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
In 3 Phase 3 studies, 8 weeks' treatment with glecaprevir/pibrentasivr produced an SVR12 in at least 93% of patients with chronic HCV genotype 2, 4, 5, or 6 infection without cirrhosis, with virologic failure in less than 1%. The drug combination had a safety profile comparable to 12 week's treatmen …
Reference Key
t2018clinicalefficacy Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Asselah T;Kowdley KV;Zadeikis N;Wang S;Hassanein T;Horsmans Y;Colombo M;Calinas F;Aguilar H;de Ledinghen V;Mantry PS;Hezode C;Marinho RT;Agarwal K;Nevens F;Elkhashab M;Kort J;Liu R;Ng TI;Krishnan P;Lin CW;Mensa FJ;;
Journal clinical gastroenterology and hepatology : the official clinical practice journal of the american gastroenterological association
Year 2018
DOI
DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/28951228
Keywords
hepatitis c National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine treatment outcome adult female male aged middle aged Clinical Trial Phase III Randomized Controlled Trial Double-Blind Method Multicenter Study Genotype antiviral agents / therapeutic use* chronic / virology antiviral agents / adverse effects placebos / administration & dosage chronic / drug therapy* hepacivirus / classification hepacivirus / genetics Quinoxalines / adverse effects Quinoxalines / therapeutic use* sulfonamides / therapeutic use* federico j mensa benzimidazoles / adverse effects sulfonamides / adverse effects pmid:28951228 doi:10.1016/j.cgh.2017.09.027 tarik asselah kris v kowdley benzimidazoles / therapeutic use* drug-related side effects and adverse reactions / epidemiology drug-related side effects and adverse reactions / pathology

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.